Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Louise Brackenbury"'
Autor:
Louise Brackenbury, Robert Nunan, Elsenoor Klaver, Paulina Goral, Tetiana Herheliuk, Lauren Kelsey, Marie Carkill
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2284688066404e1193414773ccbf4f63
Autor:
Russell Garland, Christopher Kirkham, Michelle Yap, Louise Brackenbury, Tommaso Iannitti, Robert Nunan, S Jenkinson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/531c9872398740619950be86a2829914
Autor:
Marie Carkill, Kaitlin Mitchell, Lauren Kelsey, Jezrom Self-Fordham, Nunan Robert, Louise Brackenbury
Publikováno v:
Cancer Research. 83:6377-6377
The cancer treatment landscape has transformed following the clinical success of early immune checkpoint inhibitors (ICI) which demonstrate the remarkable power of harnessing the immune system to treat a variety of metastatic cancers. Despite the suc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd117d751b42acafb3ee53fc803062a0
https://doi.org/10.1158/1538-7445.am2023-6377
https://doi.org/10.1158/1538-7445.am2023-6377
Autor:
Lauren Kelsey, Karin Latta, Joey Kolb, Bincy John, Ilona Aylott, Daniel Rocca, Alexandru Bacita, Christopher Kirkham, Patrick Walters, Charlotte Humphery, Lorena Sueiro Ballesteros, Jezrom Self-Fordham, Louise Brackenbury, Chassidy Hall, Harris David, Julia Schueler, Robert Nunan
Publikováno v:
Cancer Research. 83:4097-4097
Chimeric Antigen Receptor (CAR)-T cell therapy has achieved great success in treating a variety of liquid tumors, in particular CD19+ lymphomas. CAR technology is advancing rapidly, with notable improvements in efficacy, safety and complexity as huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51a89f5fb6184aade91288ca0c18f921
https://doi.org/10.1158/1538-7445.am2023-4097
https://doi.org/10.1158/1538-7445.am2023-4097
Publikováno v:
Cancer Research. 82:3869-3869
Chronic stimulation of CD8 T cells either as a result of viral infection or within the tumor microenvironment can lead to a state of exhaustion, whereby T cells no longer make a productive effector response. Remobilisation of exhausted tumor specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d25c04ee30ea6cfe3297a5868e35670
https://doi.org/10.1158/1538-7445.am2022-3869
https://doi.org/10.1158/1538-7445.am2022-3869
Autor:
Tommaso Iannitti, Michelle Yap, Christopher Kirkham, Russell Garland, Louise Brackenbury, S Jenkinson, Robert Nunan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Lack of efficacy is a common cause of failure in Phase I and Phase II clinical trials. Pharmacodynamic (PD) biomarker assays can demonstrate target engagement and proof of mechanism; both key components to improve trial success. Biomarkers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ea03b1312e0145eaf0a194368778b9b
https://doi.org/10.1136/jitc-2020-sitc2020.0006
https://doi.org/10.1136/jitc-2020-sitc2020.0006
Autor:
Enrique Garcia-Alvarez, Robert Nunan, Jezrom Self-Fordham, Michelle Yap, Anna Pascoe, Marie Carkill, S. Rhiannon Jenkinson, Louise Brackenbury
Publikováno v:
Cancer Research. 80:2824-2824
Cellular immunotherapy is emerging as a fifth pillar of cancer treatment. Clinical efficacy has been proven for a variety of cancers; however, its true potential has yet to be unlocked. Development of reliable and mechanistically appropriate in vitro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3d886fd9832541ae2b21aa64cbcc12a
https://doi.org/10.1158/1538-7445.am2020-2824
https://doi.org/10.1158/1538-7445.am2020-2824